Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Restructuring Costs (2024 - 2025)

Editas Medicine (EDIT) has disclosed Restructuring Costs for 2 consecutive years, with $26.1 million as the latest value for Q2 2025.

  • Quarterly Restructuring Costs changed N/A to $26.1 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $79.2 million through Sep 2025, changed N/A year-over-year, with the annual reading at $12.2 million for FY2024, N/A changed from the prior year.
  • Restructuring Costs for Q2 2025 was $26.1 million at Editas Medicine, down from $40.9 million in the prior quarter.
  • The five-year high for Restructuring Costs was $40.9 million in Q1 2025, with the low at $12.2 million in Q4 2024.